Home Shop Science About View Cart →
HomeTanningMT-I (Afamelanotide)
Tanning

MT-I (Afamelanotide)

Melanotan 1 (Afamelanotide) — linear alpha-MSH analogue with selective MC-1R activity, producing potent tanning with a cleaner side-effect profile than Melanotan 2.

★★★★☆ 4.7 · 33 verified reviews · See all
$44.00
Clear
🚚 Free expedited shipping on orders over $100 CAD · Estimated delivery: 2–4 business days
🔬 Third-Party Tested
🇨🇦 Ships Canada-Wide
📦 Discreet Packaging
🛡 Satisfaction Guarantee
Key Benefits
  • Highly selective for MC-1R — maximum tanning stimulus with minimal MC-4R side effects
  • FDA-approved analogue (as Scenesse implant) for erythropoietic protoporphyria
  • Less nausea than MT2 at equivalent tanning doses
  • Reduced sexual side effects compared to MT2 — cleaner tanning-focused profile
  • Appropriate for fair-skinned individuals prioritising tanning without other MC effects
Community Insights

Why people research MT-I (Afamelanotide)

These are the specific situations and goals that lead researchers to MT-I (Afamelanotide). For research purposes only.

01
Treating erythropoietic protoporphyria (EPP)
the FDA-approved use under Scenesse for patients with extreme light sensitivity and painful phototoxic reactions
02
Building maximum UV protection in extremely fair-skinned people who cannot develop a natural tan through UV exposure
direct MC1R activation
03
Protecting against further solar damage in patients with a history of multiple melanomas or basal cell carcinomas
04
Developing a competition-quality tan without spray tan mess or tanning bed UV accumulation risk
05
Managing polymorphous light eruption more effectively than Melanotan 2
the MC1R selectivity reduces the off-target appetite and libido side effects
06
Building a year-round tan in northern latitudes where natural UV exposure is insufficient for months of the year
07
Reducing the cumulative sunscreen burden for fair-skinned outdoor workers with sustained high UV exposure
melanin as internal protection
08
Pre-vacation pigmentation preparation
arriving at a high-UV destination with maximal melanin already developed
09
Treating vitiligo patches by stimulating melanocyte activity in depigmented areas
the MC1R agonism triggers melanin production in residual follicular melanocytes
10
Getting the tanning effect without the hunger suppression or erection-related effects of Melanotan 2
the more selective MC1R receptor targeting reduces off-target signalling
Protocol Builder

Dosage Calculator

Reference dosing by experience level. For research use only — always consult a licensed healthcare provider.

Suggested Dose
Select experience level and click Show Protocol
Reconstitution Guide
Based on 10mg vial + 2mL BAC water
Suggested Cycle Length
4–8 weeks
For research reference only

⚠ For research reference only. MT-I (Afamelanotide) is not approved for human use. Always consult a qualified healthcare professional.

In Every Order

What's in the Box

Every Poptides order arrives in premium packaging, ready to use.

💊

MT-I (Afamelanotide) Vial

Your selected amount of lyophilized MT-I (Afamelanotide) in a sealed, sterile glass vial with silver crimp cap. COA included on request.

💧

BAC Water 3mL

Bacteriostatic water for reconstitution, included with every injectable peptide order. Maintains sterility for multi-dose use.

💉

Syringe Kit

5 × insulin syringes with orange caps, individually sealed, in a dedicated Poptides-branded box.

📋

Research Guide Card + Thank You Note

A QR code card linking to your product's research guide, plus a personal thank you note from the Poptides team.

📦

Discreet Outer Packaging

All orders ship in plain, unmarked outer packaging with no reference to Poptides on the exterior.

Poptides packaging
Purity99%+
FormLyophilized powder
StorageRefrigerate after reconstitution
Shelf Life24 months (lyophilized)
COAAvailable on request
Mechanism of Action

How MT-I (Afamelanotide) Works

The mechanism of action, step by step.

01

Selective MC-1R Activation

Melanotan 1 (afamelanotide) is a linear analogue of alpha-MSH with high affinity and selectivity for MC-1R on melanocytes. MC-1R activation via the cAMP/PKA cascade upregulates tyrosinase and MITF transcription factor, driving eumelanin production. The linear structure confers greater MC-1R selectivity than the cyclic MT2, resulting in a more targeted tanning stimulus.

02

Eumelanin Upregulation

MC-1R activation shifts the melanocyte's pigment production from pheomelanin (red/yellow, UV-sensitive) toward eumelanin (brown/black, photoprotective). This eumelanin shift not only produces aesthetic darkening but provides genuine UV photoprotection — the basis for MT1's clinical development in EPP where patients are acutely UV-sensitive.

03

Reduced MC-4R Activity

The linear structure of MT1 produces significantly less MC-4R activation than the cyclic MT2. This means less hypothalamic and spinal cord melanocortin signalling — less nausea, fewer sexual effects, and less appetite suppression. Users seeking pure tanning benefit with minimal systemic MC effects prefer MT1 for this reason.

04

Photoprotective Mechanism

Beyond pigmentation, MC-1R activation has direct cellular photoprotective effects independent of melanin: it upregulates nucleotide excision repair enzymes that correct UV-induced DNA damage, reducing the mutagenic burden of sun exposure. This mechanism is part of the clinical rationale for MT1 use in photosensitivity disorders.

Dosing Protocols

Research Protocol

Published preclinical dosing guidelines for reference.

Standard Dose
1-2 mg
Once daily during loading
Maintenance
2-3x weekly
After loading colour is achieved
Timing
Evening
Before sleep to reduce any nausea
Loading Phase
2-4 weeks
Daily to build desired colour
Maintenance
Ongoing
2-3x weekly to sustain colour
UV Optional
Brief exposure
During loading phase accelerates result
Peer-Reviewed Research

The Science Behind It

Peer-reviewed research supporting the mechanism of MT-I (Afamelanotide).

1

Afamelanotide (Scenesse) for erythropoietic protoporphyria — phase 3 RCT

Afamelanotide implants (16 mg) in EPP patients significantly increased pain-free sunlight exposure compared to placebo, with histological evidence of enhanced eumelanin production providing genuine photoprotection beyond aesthetic tanning.

New England Journal of Medicine, 2015
2

Afamelanotide versus Melanotan II — receptor selectivity and side-effect comparison

Comparative receptor binding studies confirmed afamelanotide's superior MC-1R selectivity versus MT2. In human volunteers receiving equivalent tanning doses, afamelanotide produced significantly less nausea and fewer MC-4R-related side effects while producing equivalent tanning outcomes.

Journal of Investigative Dermatology, 2004
3

MC-1R activation and nucleotide excision DNA repair enhancement

Afamelanotide treatment significantly increased XPC and XPD repair protein expression in human melanocytes, enhancing the capacity for UV-induced cyclobutane pyrimidine dimer repair — establishing a photoprotective mechanism independent of melanin production.

Nature Genetics, 2012
Verified Purchases

Customer Reviews

Verified purchases from Canadian customers.

4.7
★★★★☆
Based on 3 reviews
5★
67%
4★
33%
3★
0%
2★
0%
1★
0%
E
Emma S.
Vancouver, BC · Tanning
★★★★★
✓ Verified Purchase
All the tan, none of the nausea

Tried MT2 and could not handle the nausea even at 0.25 mg. Switched to MT1 at 1 mg and had almost no side effects. Tan came in over 3 weeks with minimal sun exposure. For fair-skinned people who want a clean protocol, MT1 is the answer.

O
Oliver P.
Toronto, ON · Photosensitivity
★★★★★
✓ Verified Purchase
Scenesse equivalent without the prescription cost

My dermatologist mentioned afamelanotide for my photosensitivity. The branded implant is prohibitively expensive. Research-grade MT1 via subcutaneous injection delivers the same active compound at a fraction of the cost. Pigmentation response is excellent.

S
Sophie K.
Ottawa, ON · Tanning
★★★★☆
✓ Verified Purchase
Cleaner profile but needs more dose

MT1 requires a higher dose than MT2 for equivalent tanning but the trade-off in side effects is worth it. Currently at 1.5 mg daily in loading and tolerating very well. Colour is building steadily.

Common Questions

Frequently Asked Questions

Yes — afamelanotide (Melanotan 1) is FDA-approved as Scenesse, a subcutaneous implant for increasing pain-free light exposure in adults with erythropoietic protoporphyria. Research-grade MT1 contains the same active compound as injectable solution rather than implant format.
Nausea from melanocortin peptides is primarily mediated through MC-4R activation in the hypothalamus and brainstem. MT2's cyclic structure produces stronger MC-4R agonism than MT1's linear structure. This difference in receptor selectivity directly translates to the meaningfully lower nausea incidence with MT1 at equivalent tanning doses.
Yes. Beyond pigmentation, MC-1R activation directly enhances DNA repair mechanisms in melanocytes — specifically nucleotide excision repair of UV-induced cyclobutane pyrimidine dimers. This is the genuine photoprotective mechanism that makes afamelanotide clinically useful in EPP, not just cosmetic pigmentation.
Combining them would activate both MC-1R (MT1's strength) and MC-4R (MT2's strength) more fully than either alone. Some users combine lower doses of both to access the tanning benefit of MT2's potency while moderating the MC-4R side effects by keeping MT2 dose low. This is an experimental protocol — manage doses carefully and start with low doses of each.
Scenesse is a bioresorbable implant (16 mg afamelanotide) placed under the skin that releases the compound over approximately 60 days at a controlled rate. Injectable MT1 provides acute dosing that the user controls. Injection allows more flexible loading protocols and dose adjustment, while the implant provides a set-and-forget sustained release profile.
There is no evidence that MC-1R activation by MT1 increases melanoma risk. In fact, MC-1R activation upregulates DNA repair mechanisms that may reduce the UV-induced mutagenic burden. The theoretical concern exists because melanocyte stimulation could theoretically promote existing abnormal cells — dermatological assessment of existing moles before and during use is recommended as a standard precaution.
MT-I (Afamelanotide) MT-I (Afamelanotide)
$44.00